Background: Fondaparinux is commonly used for treatment of heparin-induced
| INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication that most commonly arises five to 10 days after exposure to heparin or low-molecular-weight heparin (LMWH).
1 Heparindependent immunoglobulin (Ig)G antibodies bind to platelet factor 4 (PF4)/heparin complexes on platelets, leading to cross-linking of platelet FcγIIa receptors. The resulting platelet activation leads to thrombocytopenia and the potential for serious venous and arterial thromboembolic complications, including death.
1
To confirm HIT, patients must have both a compatible clinical picture and laboratory confirmation of the presence of HIT antibodies.
The 4Ts score is the most commonly used prediction rule to determine the clinical pretest probability of HIT. 2 However, the range of laboratory tests for HIT antibodies is wide with a correspondingly wide variability in sensitivity and specificity. Functional assays, such as the 14 C-platelet serotonin-release assay (SRA) and the heparin-induced platelet activation (HIPA) test are considered the reference standard assays; however, enzyme-linked immunoassay (ELISA), either IgGspecific or polyspecific (detecting in addition IgA and IgM class antibodies), is more commonly used because it is commercially available and technically easier to perform.
3
If the clinical suspicion for HIT is at least moderate, it is recommended that patients be switched from heparin to an alternative nonheparin anticoagulant to reduce the likelihood of thrombosis.
4
The most commonly used drugs to treat HIT that are approved by many international health authorities are argatroban and danaparoid We excluded patients who received greater than 24 hours of another nonheparin anticoagulant (e.g, argatroban, lepirudin, danaparoid, rivaroxaban, apixaban, dabigatran); studies that did not report the name of the diagnostic assay, included fewer than five participants (to reduce the risk of reporting bias) or limited enrollment to post cardiac surgery patients who did not have the diagnosis of HIT confirmed with a functional HIT assay (i.e, patient population with a high incidence of HIT antibodies, but a low incidence of HIT).
| Inclusion criteria
Conference abstracts were also excluded.
| Study selection and data abstraction
From these studies, we extracted data on fondaparinux dose, duration of follow-up, incidence of new thrombotic events, major bleeding, and mortality due to thrombosis or bleeding. New thrombotic events included deep vein thrombosis (DVT), pulmonary embolism (PE), stroke (CVA), myocardial infarction (MI), and limb amputation.
The definition of major bleeding was accepted as reported within the individual studies. All data was independently extracted by two authors (GH and LL). Study quality was not assessed by formal criteria due to the general low quality of studies in this field.
| RESULTS
A total of 290 articles were identified using the search strategy ( Figure 1 ). After applying the inclusion/exclusion criteria as defined above and removing duplicate studies, 48 studies remained. Hand-searching of relevant reviews identified four additional studies.
Of 52 identified articles, 37 enrolled less than five patients, two did not include patients with confirmed HIT 10,11 ; one did not report clinically important outcomes, 6 two enrolled cardiac surgery patients without using a functional HIT assay, 12,13 and one did not report the outcomes according to treatment group. 14 The remaining nine studies were included in this review [15] [16] [17] [18] [19] [20] [21] [22] [23] (Table 1) .
Of the included studies, only two were prospective yielding a combined total of 32 HIT patients. 16, 17 The SRA was used to confirm HIT in all patients in two studies, 15, 16 and in selected patients in three studies. 19, 20, 22 The HIPA was used in one study 23 ; therefore, a total of 68 patients with HIT confirmed by the combination of a functional assay plus moderate/high clinical pretest probability were included in this review. All studies used either a commercial or inhouse ELISA and two studies used additional HIT antibody tests (e.g, ID-PaGIA). 16, 18 The dose of fondaparinux dose varied between 2.5 and 10 mg/kg each day, depending on body weight, and the presence of thrombosis. The mean duration of follow-up was 30 days in most studies.
A total of 154 HIT positive patients were identified of which 10 experienced a new thrombotic event while receiving fondaparinux (6.5%, 95% CI, 3.4%-11.7%). The types of thrombotic events were as follows: six venous, one arterial, and three both. Three of the thrombotic events were fatal (acute coronary syndrome; hypoxic brain injury in context of unwitnessed cardiac arrest; and unclear). There were 26 major bleeding events (16.9%, 95% CI, 11.7%-23.6%); however, the definition for major bleeding differed across the studies.
Three of the bleeding events were fatal (ruptured abdominal aortic aneurysm, gastrointestinal bleed, and postsurgical bleed with concurrent cardiac arrest). Mortality due to thrombosis or bleeding was reported for a total of five patients (3.2%, 95% CI, 1.2%-7.6%), all from the same study.
20
In the subgroup of patients who had HIT confirmed with the combination of a moderate/high 4Ts score and a functional assay (n = 68), the thrombotic event rate was 4.4% (95% CI, 1.0%-12.7%) and the bleeding event rate was 13.2% (95% CI, 6.9%-23.5%). Data on the complications in patients with a positive SRA from the study by Kang et al were not available and therefore not included in this subgroup.
| DISCUSSION
Fondaparinux is an effective and safe treatment option in patients with probable HIT. The incidence of recurrent thrombosis is low (6%) and in keeping with rates reported for anticoagulants that have been approved for the treatment of HIT. However, as with any anticoagulant, efficacy comes at the price of an increased risk of bleeding (17%).
The number of events in this review contrasts with the complete absence of events in 36 patients with probable HIT who were treated with fondaparinux in a previous narrative review by Warkentin in 2010 . 8 This discrepancy is not surprising given the larger denominator of treated patients in the current analysis (additional 118 patients). Importantly, this updated review provides reassurance that a larger proportion of patients truly had HIT due to the inclusion of three studies that confirmed HIT with functional assays (64 patients) 15 ,16,23 and two others that used the combination
F I G U R E 1 Study selection
Records identified thorugh database searching (n = 290)
Additional records identified through other sources (n = 4)
Records after duplicates removed/exclusion criteria applied (n = 52)
Full-text articles assessed for eligibility (n = 52)
Studies included in qualitative synthesis (n = 9)
Full-text aticles excluded (n = 43) Enrolled less than 5 pts (37) HIT not confirmed (2) Did not report clinically important outcomes (1) Cardiac surgery pts with no functional assay to confirm HIT (2) Outcomes not reported according to treatment group (1) of a moderate or high 4Ts score combined with a positive ELISA to confirm HIT (44 patients). 19, 20 It is noteworthy that the majority of clinical events (thrombosis, major bleeding, and associated deaths) originated from a single study. 20 Similarly, all bleeding events met the ISTH criteria for major bleeding. 24 Of note, approximately 60% of fondaparinux-treated patients had received only prophylactic doses (2.5 mg/d) in the study by Kang et al; however, the two fatal thrombotic events occurred while receiving therapeutic dose fondaparinux (unpublished data provided by author).
Interestingly, the same study by Kang et al is virtually the only reported study that also provided outcomes in argatroban-treated patients for whom laboratory testing supported a diagnosis of HIT.
When matching patients using a propensity scoring system, these authors found a similar frequency of thrombosis in antibody-positive With respect to bleeding, it is noteworthy that at least some of the included patients who experienced major bleeds had evidence of renal insufficiency at the time of the event. 23 Due to limited clinical details, it is not possible to provide an accurate proportion. However, given the dependence of fondaparinux on renal clearance and its long half-life, it is not surprising that renal insufficiency increases the risk of bleeding. This caveat should be kept in mind when using fondaparinux in the setting of decreased renal
clearance.
This review has several limitations. First, all but two of the included studies were retrospective and therefore dependent on the quality of recorded data. Second, HIT was not confirmed with a functional assay in all patients. This limitation is difficult to overcome given that most centers do not have timely access to these assays. Lastly, the dose of fondaparinux varied from prophylactic to therapeutic across the studies and it was not always clear which dose a patient was given prior to a thrombotic or bleeding event.
It is also worthy of note that fondaparinux has been documented to cause HIT on rare occasions. 8 Further, to our knowledge, there are three reported cases in which fondaparinux was used for treatment of HIT in which the patient had persistence or worsening of HIT-associated DIC and/or symptomatic thrombosis, and in whom laboratory evidence for increased platelet activation in the presence of fondaparinux was documented. [25] [26] [27] This unusual combination of demonstrable in vitro "cross-reactivity" of HIT antibodies for fondaparinux, shown using a platelet activation assay (HIPA or SRA), together with refractory HIT, suggests that in vivo cross-reactivity may be an occasional consequence of treating HIT with fondaparinux. This phenomenon is sufficiently uncommon that it was not noted in any of the papers that met the criteria for inclusion in our review. If one assumes that none of the 154 patients identified in our review developed in vivo cross-reactivity with fondaparinux, it suggests that the upper 95% CI of this adverse event is low (2.9%).
Ideally, the efficacy and safety of fondaparinux should be established by one or more methodologically rigorous randomized controlled trials. Unfortunately, due to the difficulty in conducting HIT treatment studies 28 together with the lack of interest in the manufacturer of fondaparinux to pursue HIT as an indication, it is unlikely such a study will happen. Despite the low quality of evidence, fondaparinux has still gained wide-spread acceptance as a treatment option for HIT. 6 A similar phenomenon is currently happening with direct oral anticoagulants (DOACs). 29 Oral administration gives DOACs an advantage over fondaparinux, however, there will always be a role for a parenteral agent that can be given to HIT patients who are too sick to take oral agents. This review updates the growing body of evidence that supports fondaparinux as an effective and safe option for treatment of acute HIT despite the absence of an RCT.
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